-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6237 in Facioscapulohumeral Muscular Dystrophy (FSHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6237 in Facioscapulohumeral Muscular Dystrophy (FSHD) Drug Details: RG-6237 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MT-102 in Inflammatory Bowel Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MT-102 in Inflammatory Bowel Disease Drug Details: MT-102 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-301001 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HFB-301001 in Melanoma Drug Details: HFB-301001 is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-301001 in Uterine Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HFB-301001 in Uterine Cancer Drug Details: HFB-301001 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-301001 in Renal Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HFB-301001 in Renal Cell Carcinoma Drug Details: HFB-301001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-301001 in Soft Tissue Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HFB-301001 in Soft Tissue Sarcoma Drug Details: HFB-301001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-301001 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HFB-301001 in Solid Tumor Drug Details: HFB-301001 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-301001 in Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HFB-301001 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: HFB-301001 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-301001 in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HFB-301001 in Hepatocellular Carcinoma Drug Details: HFB-301001 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AAV-GAD in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AAV-GAD in Parkinson's DiseaseDrug Details:AAV-GAD is under development for the treatment of Parkinson's disease. The therapeutic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PBF-1650 in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PBF-1650 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:PBF-1650 is under development for the treatment of psoriasis and non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HNSA-5487 in Transplant Rejection
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HNSA-5487 in Transplant RejectionDrug Details:NiceR are under development for the treatment of autoimmune disorders, transplantation and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NLX-101 in Rett Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NLX-101 in Rett SyndromeDrug Details:NLX-101 (F15599) is under development for the treatment of Rett syndrome and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trientine Hydrochloride in Congestive Heart Failure (Heart Failure)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Trientine Hydrochloride in Congestive Heart Failure (Heart Failure) Drug Details: trientine hydrochloride is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OTO-413 in Hearing Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.OTO-413 in Hearing Disorders Drug Details:OTO-413 is under development for the repair of cochlear synaptopathy and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZ-002 in Epilepsy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AZ-002 in Epilepsy Drug Details:Alprazolam (AZ-002) is under development for the treatment of seizures and epilepsy....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pemvidutide in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pemvidutide in Obesity Drug Details: Pemvidutide (ALT-801) is under development for the treatment of obesity,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-200603 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HFB-200603 in Gastric CancerDrug Details:HFB-200603 is under development for the treatment of solid tumor, renal cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-200603 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HFB-200603 in Colorectal CancerDrug Details:HFB-200603 is under development for the treatment of solid tumor, renal cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-200603 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HFB-200603 in Solid TumorDrug Details:HFB-200603 is under development for the treatment of solid tumor, renal cell...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.